Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation

Company Overview - Gossamer Bio Inc. (NASDAQ:GOSS) is a pharmaceutical company focused on the discovery, development, and marketing of treatments in the fields of immunology, inflammation, and oncology [3]. Investment Ratings - H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Gossamer Bio and set a price target of $10 for the stock [1]. - Barclays initiated coverage on Gossamer Bio with an Overweight rating and a price target of $9, highlighting that biotech stocks like Gossamer Bio are undervalued and could benefit from ongoing mergers and acquisitions [1]. - Cantor Fitzgerald also maintains an Overweight rating on Gossamer Bio, with expectations for results from its clinical trial of seralutinib in pulmonary arterial hypertension to be released in mid to late February [2]. Clinical Trials and Data - Gossamer Bio is expected to present additional imaging data related to its clinical trials in the second quarter of 2026 [2].